Martine Rothblatt, the CEO of United Therapeutics Corp (UTHR), sold $15.41 million of company stock in the seven day window ending October 8th, 2026. The selling was spread across 47 separate Form 4 filings. Only open market sales are counted here, which means Form 4 transaction code S.
That total covers a single name. Rothblatt was the only insider at United Therapeutics recorded as selling in the window, and the largest seller in the window by default. Shares withheld to cover taxes and disposals back to the issuer are excluded from the figure, so what is left is stock sold into the market.
United Therapeutics is a pharmaceutical preparations company. Its last price in our table is $550.10, against a market capitalization of $23,594,168,320. A run of filings this dense in a single week is worth noting on its own terms, separate from any view on the business.
The distinct seller count for the window is one. That matters for how the activity reads. A single executive selling repeatedly looks different from a broad group of officers and directors reducing holdings at the same time, even when the dollar totals are similar. Here there is no second name on the list.
The 47 filings also deserve context. A high filing count over a short period is often the signature of many small executions reported individually rather than one large block trade. The reconciled total for the window is $15.41 million regardless of how the executions were broken up.
A sale is not advice and it is not a prediction. A sale may be a scheduled 10b5-1 plan entered months earlier, with the dates and amounts set well before the week in which the trades printed. Executives sell stock for reasons that have nothing to do with the company: taxes, diversification, estate planning, charitable giving, or a personal purchase. Nothing in a Form 4 explains motive, and nothing above should be read as an opinion on United Therapeutics or on what the shares will do next.
What this article is, is a record of what was filed. The filings show who sold, when, and how much. They do not show why, and we do not guess. Readers who want to judge the pattern should look at the longer history of insider activity at the company rather than any single week, including whether similar clusters of sales have appeared before.
Figures in this article come from SEC Form 4 filings via EDGAR, reviewed by InsiderBuying.com, covering the seven day window ending October 8th, 2026.
Track every Form 4 filed at UNITED THERAPEUTICS Corp (UTHR) → insiderbuying.com/companies/UTHR